SPOTLIGHT: Gilmartin testifies in Vioxx trial
Vioxx was important to Merck's financial future when the company launched the drug as other key patents were set to expire, according to testimony by the former CEO of the drug giant. But Raymond Gilmartin insisted that the company did not put profits ahead of safety in pushing the drug out into the marketplace. His videotaped deposition was played by Merck as part of its defense in a Texas trial. Story
Comments